5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Direct factor Xa (FXa) inhibitors are increasingly prescribed for outpatients, and those transitioning to unfractionated heparin (UFH) for hospital admission are monitored via an anti-FXa assay. Because of assay interference, UFH results would often be critically elevated, confounding dosing.

          Related collections

          Author and article information

          Journal
          J Thromb Haemost
          Journal of thrombosis and haemostasis : JTH
          Wiley
          1538-7836
          1538-7836
          July 2020
          : 18
          : 7
          Affiliations
          [1 ] Special Coagulation Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
          [2 ] College of Pharmacy, University of Michigan Medical School, Ann Arbor, MI, USA.
          [3 ] Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA.
          Article
          10.1111/jth.14806
          32216028
          51badf4f-e2ac-4c54-b935-7d1fc4ea7e9a
          © 2020 International Society on Thrombosis and Haemostasis.
          History

          apixaban,drug monitoring,factor IIa,heparin,rivaroxaban
          apixaban, drug monitoring, factor IIa, heparin, rivaroxaban

          Comments

          Comment on this article